LONDON (Reuters) - U.S. regulators gave priority review status to an experimental GlaxoSmithKline drug for HIV/AIDS, which industry analysts view as a possible multibillion-dollar-a-year seller. The U.S. Food and Drug Administration awards certain drugs priority status when they have the potential to offer significant improvement over existing treatments. The agency is due to give its verdict on whether to approve dolutegravir by August 17, Britain's biggest drugmaker said on Friday. ...
Original Source
No comments:
Post a Comment